Clinical Trial: Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07382687) titled 'Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype' on Jan. 27.

Brief Summary: This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. This study aims to investigate the efficacy and safety of Famitinib combination with SHR-A1811 in CDK4/6 inhibitors-resistent advanced HR+/HER2- breast cancer with SNF4 subtype.

Study Start Date: Feb. 26

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: SHR-A1811

SHR-A1811 4.8mg/kg iv q3w

DRUG: Famitinib+SHR-A1811

Famitinib 10mg po qd SHR-A181...